{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:07Z","timestamp":1786994407710,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.msard.2018.06.015","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:25:14Z","timestamp":1530750314000},"page":"113-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Efficacy and safety of natalizumab extended interval dosing"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-6651","authenticated-orcid":false,"given":"Bassem I.","family":"Yamout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohamad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil El","family":"Ayoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Tamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3198-6063","authenticated-orcid":false,"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3405-8967","authenticated-orcid":false,"given":"Maya M","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2018.06.015_bib0017","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.msard.2018.06.015_bib0004","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2018.06.015_bib0008","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2018.06.015_bib0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"Kempen","year":"2018","journal-title":"Multiple Sclerosis J."},{"issue":"5","key":"10.1016\/j.msard.2018.06.015_bib0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"issue":"S3","key":"10.1016\/j.msard.2018.06.015_bib0007","first-page":"659","article-title":"New algorithm to estimate risk of natalizumab-associated progressive multifocal leukoencephalopathy (PML) in anti-JCV antibody positive patients: analyses of clinical trial data to provide further temporal precision and inform clinical practice","volume":"22","author":"Koendgen","year":"2016","journal-title":"Multiple Sclerosis J."},{"issue":"11","key":"10.1016\/j.msard.2018.06.015_bib0002","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Linda","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.msard.2018.06.015_bib0009","first-page":"1280","article-title":"More on JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"369","author":"Major","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2018.06.015_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2018.06.015_bib0006","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2018.06.015_bib0003","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2018.06.015_bib0014","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/cyto.b.21527","article-title":"Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients","volume":"94","author":"Punet-Ortiz","year":"2018","journal-title":"Cytometry B Clin. Cytom."},{"issue":"4","key":"10.1016\/j.msard.2018.06.015_bib0013","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.msard.2018.06.015_bib0001","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2018.06.015_bib0016","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","article-title":"A safety and pharmacokinetic study of intravenous natalizumab in patients with MS","volume":"52","author":"Sheremata","year":"1999","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2018.06.015_bib0011","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2018.06.015_bib0012","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.06.015_bib0018","article-title":"Exploratory PML risk assessment on Extended Interval Natalizumab Dosing","author":"Zhovtis Ryerson","year":"2017","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:17Z","timestamp":1761900077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":18,"alternative-id":["S2211034818301925"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.06.015","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of natalizumab extended interval dosing","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}